Flow chart summarizing when mutation analysis is recommended in CML patients treated with imatinib first-line. CHR indicates complete hematologic response; PCyR, partial cytogenetic response; CCA/Ph⁺, appearance of clonal chromosomal abnormalities in the Ph⁺ clone as detected by chromosome banding analysis.